Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
The subject and/or their guardian signs a written informed consent form and is willing to comply with the long-term follow-up protocol and supporting protocols.
Adult or pediatric patients (aged ≥ 4 years) diagnosed with AIPL1-IRD.
Definitive molecular diagnosis of biallelic AIPL1 gene mutations confirmed by next-generation sequencing combined with Sanger validation.
The study eye has a best-corrected visual acuity of no more than 58 letters (approximately equivalent to decimal visual acuity ≤ 0.3) using the ETDRS visual acuity chart at baseline.
A history of ocular diseases that, in the investigator's judgment, may hinder the planned treatment or interfere with the interpretation of study endpoints (e.g., glaucoma, diabetic retinopathy, retinal vein occlusion, retinal detachment, posterior or panuveitis, etc.).
Any eye with a history of gene therapy for IRD or other hereditary neuro-ophthalmic diseases (including but not limited to other viral vector-based gene therapies, mRNA therapies, etc.).
A lack of sufficient viable retinal cells as determined by non-invasive methods such as OCT or ophthalmoscopy.
Any active intraocular or periocular infection in the study eye (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis).
Single group
LX107 Injection
GeneticSubjects will receive subretinal injection of LX107 on Day 0.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) following LX107 subretinal injection
Changes in Functional Magnetic Resonance Imaging (fMRI) Results
Mean Change from Baseline in Multi-luminance Mobility Test (MLMT)
Assess the subject's mobility ability under different light intensities using MLMT, and compare the mean changes from baseline at 180 and 365 days after treatment to reflect improvements in visual function.
Mean Change from Baseline in Full-Field Sensitivity Threshold (FST)
Measure the subject's light perception ability using FST, and compare the mean changes from baseline at 180 and 365 days after treatment to evaluate improvements in visual sensitivity.
Mean Change from Baseline in Visual Acuity (VA)
Measure VA using ETDRS and BRVT charts, with LogMAR score as the indicator, and compare the mean changes from baseline at 180 and 365 days after treatment to assess visual acuity improvement.
Click on the lead sponsor to view all of their trials.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Collaborator
